Apimeds Pharmaceuticals Files 10-K Amendment
Ticker: APUS · Form: 10-K/A · Filed: May 2, 2025 · CIK: 1894525
| Field | Detail |
|---|---|
| Company | Apimeds Pharmaceuticals Us, INC. (APUS) |
| Form Type | 10-K/A |
| Filed Date | May 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals
TL;DR
Apimeds filed an amendment to its 2024 10-K, check for updates.
AI Summary
Apimeds Pharmaceuticals US, Inc. filed an amendment (Amendment No. 1) to its annual report on Form 10-K for the fiscal year ended December 31, 2024. The filing, dated May 2, 2025, provides updated information for the company, which is incorporated in Delaware and headquartered in Hopewell, NJ. The company operates in the Pharmaceutical Preparations industry.
Why It Matters
This amendment provides updated financial and operational information for Apimeds Pharmaceuticals US, Inc., crucial for investors and stakeholders to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This is a routine amendment to an annual report, not indicating new or significant risks.
Key Numbers
- 001-42545 — Commission File Number (Identifies the company's SEC filings)
- 85-1099700 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Apimeds Pharmaceuticals US, Inc. (company) — Registrant
- 2024 (date) — Fiscal year end
- May 2, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Hopewell, NJ (location) — Principal executive offices
FAQ
What specific information was updated in this 10-K/A amendment?
The filing is an amendment to the Form 10-K for the fiscal year ended December 31, 2024, indicating updates to previously filed information, though the specific details of the amendments are not provided in this header.
When was the original 10-K filed?
The filing header indicates this is Amendment No. 1 to the Form 10-K for the fiscal year ended December 31, 2024, filed as of May 2, 2025. The original filing date is not explicitly stated but would precede this amendment.
What is the primary business of Apimeds Pharmaceuticals US, Inc.?
Apimeds Pharmaceuticals US, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where is Apimeds Pharmaceuticals US, Inc. headquartered?
The company's principal executive offices are located at 2 East Broad Street, 2nd Floor, Hopewell, NJ 08525.
What is the SEC file number for Apimeds Pharmaceuticals US, Inc.?
The Commission File Number for Apimeds Pharmaceuticals US, Inc. is 001-42545.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on May 2, 2025 regarding Apimeds Pharmaceuticals US, Inc. (APUS).